Akums Drugs receives approval for manufacturing Bempedoic Acid tablets in India
Akum's research and development teams are working on various combinations of Bempedoic plus other molecules, and soon these innovative products will also be introduced in India
Akums Drugs and Pharma has acquired the licence to manufacture and commercialise the drug named Bempedoic acid. Known as a novel, non-statin lipid-lowering treatment option that’s taken orally, Bempedoic acid is a new class of drug for treating high LDL-cholesterol conditions that’s indicative of cardiovascular diseases. Since Bempedoic acid is known to be low-risk for patients with intolerability for statins, it’s beneficial to Indian population that has a high incidence of LDL and heart diseases, the company informed via a statement.
The company will soon begin manufacturing this novel, first-in-India, lipid-lowering drug. Its research and development teams are working on various combinations of Bempedoic plus other molecules, and soon these innovative products will also be introduced in India, added the statement.
Speaking in this regard, Sanjeev Jain, founder, Promoter and Director, Akums Drugs and Pharma, said in the statement, “This therapy is an important addition to the management of dyslipidaemia through effective disease management, and we’re happy that Akums Drugs has acquired the licence to manufacture Bempedoic acid. Bempedoic acid has shown positive results in supporting therapy in patients unable to tolerate or unresponsive to statins, which accounts for about 5.4 million Indian patients. This puts the drug in a class of its own, with the ability to do something that was till now unthinkable. At Akums Drugs, we are glad to be a part of such path-breaking initiatives and hope that together with our customers in pharma, we will capture significant market share and be the pioneers in introducing the complete range of Bempedoic acid.”